BIAF

bioAffinity Technologies, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-16

Figures on this page computed 2026-11-08 12:40 UTC

Last close

2.72USD

Market data, 2026-11-06

Except where said otherwise: 10-K for 2025, filed 2026-03-16

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001493152-26-010143
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-16
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001493152-26-010143
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-07
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-07
The filing itself
-242.0%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001493152-26-010143
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
-152.4%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001493152-26-010143
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-K for 2025, filed 2026-03-16
The filing itself
0.16Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001493152-26-010143
Reported in
USD
- 10-K for 2025, filed 2026-03-16
- 10-Q for 2025, filed 2026-08-07
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.21 against 0.46 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.81x

1.83x

1.77x

0.38x

0.01x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-06

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-16

Sales0.81x
Its own average over 4 years, 7.6M.
Profit1.83x
Its own average over 7 years, -8.1M.
Free cash flow1.77x
Its own average over 6 years, -5.3M.
Debt0.38x
Its own average over 6 years, 3.1M.
Price0.01x
Its own average over 5 years, 529. Market data, 2026-11-06

Price is furthest from its own average, at 0.01 times.

Sales is 0.81 times its own 4-year average; Profit is 1.83 times its own 7-year average; Free cash flow is 1.77 times its own 6-year average; Debt is 0.38 times its own 6-year average; Price is 0.01 times its own 5-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-16

Sales against its own 4-year average0.81
Source
filed
Statement
income
Fiscal year
2025
Accession
0001493152-26-010143
Reported in
USD
The filing itself
Profit against its own 7-year average1.83
Source
filed
Statement
income
Fiscal year
2025
Accession
0001493152-26-010143
Reported in
USD
The filing itself
Free cash flow against its own 6-year average1.77
Source
filed
Statement
income
Fiscal year
2025
Accession
0001493152-26-010143
Reported in
USD
The filing itself
Debt against its own 6-year average0.38
Source
filed
Statement
income
Fiscal year
2025
Accession
0001493152-26-010143
Reported in
USD
The filing itself
Price against its own 5-year average0.01Market data, 2026-11-06
Source
market
Taken on
2026-11-06
Reported in
USD